TD-198946

CAS No. 364762-86-7

TD-198946( TD-198946 | TD 198946 | TD198946 )

Catalog No. M17496 CAS No. 364762-86-7

TD-198946, a potent chondrogenic agent, is a thienoindazole derivative.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 143 In Stock
5MG 222 In Stock
10MG 357 In Stock
25MG 597 In Stock
50MG 851 In Stock
100MG 1152 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TD-198946
  • Note
    Research use only, not for human use.
  • Brief Description
    TD-198946, a potent chondrogenic agent, is a thienoindazole derivative.
  • Description
    TD-198946 is a thienoindazole derivative, has been found to be active in the studies as a chondrogenic factor. Cell-sheet technology combined with a thienoindazole derivative small compound TD-198946 for cartilage regeneration. A novel disease-modifying osteoarthritis drug candidate targeting Runx1.
  • In Vitro
    TD-198946 is a potent chondrogenic agent. TD-198946 strongly induces chondrogenic differentiation without promoting hypertrophy in cell and metatarsal organ cultures. TD-198946 induces stronger Col2a1 promoter activity than insulin in ATDC5 cells. In C3H10T1/2 cells, ATDC5 cells and primary mouse chondrocytes, TD-198946 dose-dependently stimulates endogenous expression of the chondrocyte markers Col2a1 and Acan, with maximum effects around 1-10 μM.
  • In Vivo
    When administered directly into the joint space, TD-198946 successfully prevents and repaires degeneration of the articular cartilage. TD-198946 exerts its effect through the regulation of Runx1 expression, which is downregulated in both mouse and human OA cartilage compared with normal tissue. TD-198946 has disease-modifying effects on progressed osteoarthritis. TD-198946 may prevent the progression of osteoarthritis by acting on the remaining chondrocytes rather than repairing damaged cartilage, it may be most effective as a therapeutic during the early or middle stages of osteoarthritis, before the articular cartilage is fully eroded. Cartilaginous cell-sheets are generated by culturing mouse and canine costal chondrocytes and human mesenchymal stem cells with TD-198946 on temperature-responsive dishes. The transplanted cell-sheets are then successfully used to promote the reconstruction of permanent cartilage, with no evidence of chondrocyte hypertrophy in the knee articular cartilage defects created in mice and canines.
  • Synonyms
    TD-198946 | TD 198946 | TD198946
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    364762-86-7
  • Formula Weight
    482.55
  • Molecular Formula
    C27H22N4O3S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 28 mg/mL; 58.03 mM
  • SMILES
    Cn1c2c(CCc3c(sc(c23)Oc2ccc(cc2)OCc2nc3ccccc3cc2)C(=O)N)cn1
  • Chemical Name
    1-Methyl-8-[4-(quinolin-2-ylmethoxy)phenoxy]-4,5-dihydrothieno[3,4-g]indazole-6-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Yano F, et al. A novel disease-modifying osteoarthritis drug candidate targeting Runx1. Ann Rheum Dis. 2013 May;72(5):748-53.
molnova catalog
related products
  • Glycyl-glycine

    Glycylglycine (Gly-Gly) is a dipeptide used in biochemical research. It is the simplest of all dipeptides and is used as a starting template for preparation of more complex peptides. Glycine is involved in the body's production of DNA phospholipids and collagen and in the release of energy.

  • Succimer

    Succimer is a Lead Chelator. The mechanism of action of succimer is as a Lead Chelating Activity.

  • Vazegepant HCl

    Vazegepant is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study.